Vimarsana
Biggest News Aggregation in the World

Page 7 - Impacts Questionnaire News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Impacts Questionnaire. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Impacts Questionnaire Today - Breaking & Trending Today

GNW: FDA accepts the new drug application for review of Idorsia's daridorexant | Newsticker - Vimarsana News

GNW: FDA accepts the new drug application for review of Idorsia's daridorexant | Newsticker

for the treatment of adult patients with insomnia •      The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety profile Allschwil, Switzerland - March 10, 2021 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia's investigational dual orexin receptor antagonist, daridorexant, for the treatment of ad...

Source: fuw.ch
Idorsia Pharmaceuticals Ltd: FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult patients with insomnia - Vimarsana News

Idorsia Pharmaceuticals Ltd: FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult patients with insomnia

Idorsia Pharmaceuticals Ltd: FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult patients with insomnia Allschwil, Switzerland - March 10, 2021 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia's investigational dual orexin receptor antagonist, daridorexant, for the treatment of adult patients with insomnia. Insomnia is a common problem with approximately 25 million adults in the US who meet the diagnostic criteria. Insomnia, a condition of o...

Idorsia Pharmaceuticals Ltd: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia - Vimarsana News

Idorsia Pharmaceuticals Ltd: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia

• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime